MCK Stock Analysis — McKesson
Sector: Healthcare Distribution
AI Verdict
McKesson trades at 18.7x next year's earnings with 24.4% EPS growth expected, making it cheap for the growth you're getting if its distribution moat keeps competitors at bay.
Competitive Moat
McKesson operates one of the largest pharmaceutical distribution networks in North America, giving it scale advantages and entrenched relationships with hospitals and pharmacies. Its logistics infrastructure and regulatory expertise create high switching costs for customers reliant on uninterrupted drug supply.
Summary
McKesson's forward P/E of 18.7x with 24.4% expected EPS growth makes it a rare high-growth, defensive healthcare play.
Where It Stands
The stock is up 30.06% over the past year, trades at 18.7x next year's earnings versus the healthcare sector median of 22x, and its RSI of 59.7 is neutral, showing neither overbought nor oversold conditions.
Key Metrics
- RSI: 59.7 — Neutral
- Trailing P/E: 23.3x
- Forward P/E: 18.7x
- PEG Ratio: 0.96
- Earnings Growth: +0.2%
- Revenue Growth: +0.1%
- Market Cap: $101.4B
- Dividend Yield: 0.00%
- 1-Year Return: 30.06%
- 52-Week High: $999.00
- 52-Week Low: $637.00
Analyst Consensus
20 Buy · 3 Hold · 0 Sell (23 analysts)
Bull Case
You are paying 18.7x forward earnings for a company expected to grow EPS by 24.4% next year, which is cheap for this level of growth in a defensive sector.
Bear Case
If the P/E multiple reverts to the sector median of 22x from its current 23.3x trailing, the stock could see a valuation-driven pullback despite solid fundamentals.
Catalyst to Watch
Watch for quarterly earnings surprises or regulatory changes affecting drug distribution margins, as either could materially shift earnings expectations.